SmallCaps
ASX:TLXPharmaceuticals, Biotechnology & Life SciencesBiotechnology

Telix Pharmaceuticals Ltd

$13.470
Day Range
$13.160 – $13.810
52 Week Range
$8.260 – $26.250
Volume
0.00
Avg Volume (10D)
1.95M
Market Cap
$4.57B
Price Chart
Market Statistics
Open$13.470
Previous Close$13.470
Day High$13.810
Day Low$13.160
52 Week High$26.250
52 Week Low$8.260
Valuation
Market Cap4.57B
Shares Outstanding339.38M
Price to Book7.76
Trading Activity
Volume0.00
Value Traded0.00
Performance
1 Day1.05%
5 Day7.13%
13 Week25.74%
52 Week-47.92%
YTD20.80%
Technical Indicators
RSI (14)48.14
50-Day SMA$14.188
200-Day SMA$13.353
Latest News
Weekly Wrap: Strong Week Despite Late Fade
Hot Topics

Weekly Wrap: Strong Week Despite Late Fade

ASX up 4.4% for the week; strongest since Oct 2022, despite Friday fade. Magellan-Barrenjoey merger approved; Telix jumps on US regulator nod; Iran talks ahead.

Telix Pharmaceuticals to acquire Canadian isotope innovator ARTMS in $125.9m deal
ASX 200

Telix Pharmaceuticals to acquire Canadian isotope innovator ARTMS in $125.9m deal

Australian biopharmaceutical company Telix Pharmaceuticals (ASX: TLX) is set to acquire Canadian radioisotope technology firm ARTMS Inc in a $125.9 million deal designed to boost its supply chain and production capacity. The deal will include ARTMS’ advanced cyclotron-based isotope production platform, a manufacturing plant and a stockpile of ultra-pure rare metals required for consumable target […]

Medibank suffers cyberattack, Telix Pharma expands GE Healthcare partnership and APA Group to acquire Basslink
ASX 200

Medibank suffers cyberattack, Telix Pharma expands GE Healthcare partnership and APA Group to acquire Basslink

Health insurance provider Medibank Private’s (ASX: MPL) shares are down this week after the company revealed it suffered a major cyber security incident. Despite the concern, the provider urged there was no evidence of customers’ data being accessed and has since returned to business as usual. Medibank has a large database, covering more than 3.7 […]

Telix withdraws Europe marketing application, AGL to close power station early and BHP prioritises Peru exploration
ASX 200

Telix withdraws Europe marketing application, AGL to close power station early and BHP prioritises Peru exploration

Telix Pharmaceuticals (ASX: TLX) has announced it has withdrawn its application to market the company’s lead prostate cancer imaging product, Illuccix, in Europe. The Danish Medicines Agency asked for additional chemistry, manufacturing and control data from Telix, but the Australian company said the requests could not be delivered within the prescribed review timeframe. Telix group […]